Please note: You’ll get an immediate assessment when you request PBS authorities online.
Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with adalimumab under the National Health Act 1953, section 85 for patients with non-infectious uveitis.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing adalimumab.
Treatment specifics
To be eligible for PBS-subsidised treatment with adalimumab, patients must be treated by, or in consultation with either:
- an ophthalmologist
- a rheumatologist
- an immunologist with expertise in uveitis.
Authority applications
Applying for initial treatment
Applications for initial authority approval to prescribe PBS-subsidised adalimumab to treat non-infectious uveitis can be made either in:
- real time using the Online PBS Authorities system
- writing and use HPOS Form upload
- writing and mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed non-infectious uveitis - adalimumab - initial authority application form
- relevant attachments.
Applying for initial grandfather treatment
For patients who received non-PBS-subsidised adalimumab treatment before 1 August 2024 for non-infectious uveitis, apply for initial grandfather authority approval either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Applying for recommencement of treatment
Applications to recommence authority approval to prescribe PBS-subsidised adalimumab to treat non-infectious uveitis can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Applying for continuing treatment
Applications for continuing authority approval to prescribe PBS-subsidised originator brand of adalimumab to treat non-infectious uveitis can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Application for continuing PBS-subsidised treatment with biosimilar brands of adalimumab is Authority Required (Streamlined). You don’t need authority approval from us for the listed quantities and repeats.
More information
Call the PBS Complex Drugs Programs enquiry line for more information.